Objective: Achieving first-cycle approval in Abbreviated New Drug Applications (ANDAs) is a critical goal in the generic drug industry, as it enables faster market entry. This study covers common areas of deficiency within ANDA submissions that often lead to delays and multiple review cycles. This review also delves into FDA initiatives aimed at improving first-cycle approval rates and case study analysis that assess deficiencies impact on approval timelines.
Method: A literature-based analysis was conducted, reviewed industry reports, regulatory guidelines, and published articles available on various databases to identify trends in ANDA deficiencies.
Result: Identifies key areas where applicants frequently fall short, such as incomplete data submissions, inadequate manufacturing, labelling and DMF requirements, and insufficient bioequivalence studies.
Conclusion: Overall, it provides valuable insights and practical guidance for generic drug developers to refine their submissions, aiming for higher first-cycle approval success in alignment with FDA standards.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s43441-025-00755-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Regulatory Frameworks and Filing Discrepancies in Generic Drug Approvals: A Cross-Regional Study with Analysis of FDA ANDA Deficiencies.
Ann Pharm Fr
March 2025
Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management SVKM's NMIMS, V. L. Mehta Road, Vile Parle (W), Mumbai, 400056, India. Electronic address:
Objectives: This research aims to analyse the regulatory frameworks for generic drug applications in the US, EU, India, Japan, and China comparing their filing requirements to identify gaps and areas for harmonization. Additionally, it focuses on examining common deficiencies in ANDA from FDA submissions in 2014-2023 to address issues, facilitating more efficient approvals and minimizing delays.
Material And Methods: The research involved analysing regulatory documents available on official websites, including the FDA, EMA, CDSCO, PMDA, and NMPA to achieve first objective.
Impact of Filgrastim on Mortality During Induction Chemotherapy in Childhood B-Cell Non-Hodgkin Lymphoma.
Cureus
January 2025
Pediatric Oncology, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, PAK.
Background Childhood B-cell non-Hodgkin lymphoma (NHL) is a group of rapidly growing neoplasms that are fatal if left untreated. Induction chemotherapy during the treatment makes these patients vulnerable to several life-threatening infections due to their immunocompromised state. Prophylactic use of filgrastim before initiating the second induction chemotherapy cycle can improve outcomes.
View Article and Find Full Text PDFFocusing on First Cycle Approval in ANDA Submission: Understanding Common Deficiencies & Case Study Insights.
Ther Innov Regul Sci
February 2025
Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management SVKM's NMIMS, V. L. Mehta Road, Vile Parle (W), Mumbai, 400056, India.
Objective: Achieving first-cycle approval in Abbreviated New Drug Applications (ANDAs) is a critical goal in the generic drug industry, as it enables faster market entry. This study covers common areas of deficiency within ANDA submissions that often lead to delays and multiple review cycles. This review also delves into FDA initiatives aimed at improving first-cycle approval rates and case study analysis that assess deficiencies impact on approval timelines.
View Article and Find Full Text PDFStrategies to manage the adverse effects of immunotherapy with dinutuximab beta in neuroblastoma: an Italian experience and literature review.
Support Care Cancer
February 2025
Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milano, Italy.
Purpose: Patients with high-risk neuroblastoma (HR NB) frequently present with metastases in the bone marrow and bone. Approximately 15% of these patients are refractory to induction therapy, and 50% relapse. Dinutuximab beta is an anti-GD2 monoclonal antibody approved in Europe for maintenance therapy of pediatric patients with HR NB.
View Article and Find Full Text PDFA stage IIIA lung adenocarcinoma case achieving pathological response with only one cycle of preoperative nivolumab combination chemotherapy.
Gen Thorac Cardiovasc Surg Cases
February 2025
Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Background: Preoperative nivolumab combination chemotherapy has shown its efficacy in resectable stage II-III non-small cell lung cancer and become one of the standard treatments. While preoperative nivolumab combination chemotherapy is generally a regimen of three cycles, the efficacy of nivolumab combination chemotherapy when treatment is prematurely discontinued remains unclear.
Case Presentation: An 81-year-old man was diagnosed as lung adenocarcinoma (cT3N1M0, cStage IIIA).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!